Jazz Pharmaceuticals PLC Company Profile (NASDAQ:JAZZ)

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

What is Jazz Pharmaceuticals PLC's stock symbol?

Jazz Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals PLC's earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) posted its quarterly earnings data on Tuesday, August, 8th. The company reported $1.72 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.85 by $0.13. The company had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The company's quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.67 earnings per share. View Jazz Pharmaceuticals PLC's Earnings History.

When will Jazz Pharmaceuticals PLC make its next earnings announcement?

What guidance has Jazz Pharmaceuticals PLC issued on next quarter's earnings?

Jazz Pharmaceuticals PLC updated its FY17 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $10.70-11.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.02. The company issued revenue guidance of $1.625-1.7 billion, compared to the consensus revenue estimate of $1.66 billion.

Where is Jazz Pharmaceuticals PLC's stock going? Where will Jazz Pharmaceuticals PLC's stock price be in 2017?

What are analysts saying about Jazz Pharmaceuticals PLC stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals PLC stock:

1. According to Zacks Investment Research, "Jazz’s largest franchise is its sleep disorder portfolio. The company’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. Its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. Moreover, In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which was completed in early Apr 2017. Jazz’ shares outperformed the industry so far this year. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions this year. Estimates have been stable lately ahead of the company’s Q2 earnings release." (8/8/2017)

2. Cantor Fitzgerald analysts commented, "Meetings highlight view that late-stage assets are underappreciated. We hosted meetings with the CEO in the Midwest last week. Investors he met with expressed interest in Xyrem, of course, but the bulk of the questions centered around the pipeline. A common theme was that JZP-110 may be underestimated by the Street. We also spoke with some investors who seem to be gaining appreciation for the potential of the low-sodium oxybate formulations. Vyxeos approval could be around the corner. The PDUFA date for Vyxeos is September 30, and management commented that Breakthrough-designated drugs have been approved before the statutory date." (6/27/2017)

4. Cowen and Company analysts commented, "complete re-rating."Cacciatore comments, "We continue to believe Jazz is nearing a very interesting inflection point, as a favorable resolution to the Xyrem litigation is likely, which could extend the franchise to 2024/2025. Combined with JZP-110's potential $750MM+ opportunity to complement growing Defitelio, Erwinaze, and ultimately Vyxeos, we believe a complete re-rating is nearing. We would add here." (3/20/2017)

5. BMO Capital Markets analysts commented, "JAZZ delivered on an important milestone with positive Phase 3 data for JZP-110 in two OSA studies that appear to demonstrate a very solid clinical profile for this novel wake-promoting agent. There had been some concerns into these data (first OSA studies for JZP-110), and we think this outcome significantly de-risks the program; Phase 3 data in narcolepsy set for 2Q17 and filing in late 2017. We reiterate our Outperform; JAZZ remains a top pick." (3/20/2017)

Are investors shorting Jazz Pharmaceuticals PLC?

Jazz Pharmaceuticals PLC saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 2,492,906 shares, an increase of 39.2% from the August 15th total of 1,790,242 shares. Based on an average trading volume of 533,555 shares, the short-interest ratio is presently 4.7 days. Approximately 4.3% of the shares of the company are short sold.

Jazz Pharmaceuticals PLC's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, JPMorgan Chase & Co., American Century Companies Inc., Zurcher Kantonalbank Zurich Cantonalbank, Balyasny Asset Management LLC, Vanguard Group Inc. and Pioneer Investment Management Inc.. Company insiders that have bought Jazz Pharmaceuticals PLC stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.